EGF and prostate cancer: Based on the quantification of HB-EGF in vitro, our results demonstrated that the treatment of MDA-MB-231 breast and PC3 prostate cancer cells with LPA1–3 antagonists (Ki16425, Debio0719) mimicked Lpar1 gene silencing in MDA-B02 breast cancer cells.